RT Journal Article
SR Electronic
T1 Clinical validation of colorimetric RT-LAMP, a fast, highly sensitive and specific COVID-19 molecular diagnostic tool that is robust to detect SARS-CoV-2 variants of concern
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.05.26.21257488
DO 10.1101/2021.05.26.21257488
A1 Alves, Pedro A.
A1 Oliveira, de Ellen G.
A1 Franco-Luiz, Ana Paula M.
A1 Almeida, Letícia T.
A1 Gonçalves, Amanda B.
A1 Borges, Iara A.
A1 Rocha, Flávia de S.
A1 Rocha, Raissa P.
A1 Bezerra, Matheus F.
A1 Miranda, Pâmella
A1 Capanema, Flávio D.
A1 Martins, Henrique R.
A1 Weber, Gerald
A1 Teixeira, Santuza M. R.
A1 Wallau, Gabriel Luz
A1 do Monte-Neto, Rubens L.
YR 2021
UL http://medrxiv.org/content/early/2021/06/02/2021.05.26.21257488.abstract
AB The COVID-19 pandemics unfolded due to the widespread SARS-CoV-2 transmission reinforced the urgent need for affordable molecular diagnostic alternative methods for massive testing screening. We present the clinical validation of a pH-dependent colorimetric RT-LAMP (reverse transcription loop-mediated isothermal amplification) for SARS-CoV-2 detection. The method revealed a limit of detection of 19.3 ± 2.7 viral genomic copies/μL when using RNA extracted samples obtained from nasopharyngeal swabs collected in guanidine-containing viral transport medium. Typical RT-LAMP reactions were performed at 65 ºC for 30 min. When compared to RT-qPCR, up to Ct value 32, RT-LAMP presented 97% (87.4-99.4% 95% CI) sensitivity and 100% (86.2-100%) specificity for SARS-CoV-2 RNA detection targeting N gene. No cross-reactivity was detected when testing other non-SARS-CoV virus, confirming high specificity. The test is compatible with primary RNA extraction free samples. We also demonstrated that colorimetric RT-LAMP can detect SARS-CoV-2 variants of concern (VOC) and variants of interest (VOI), such as variants occurring in Brazil named P.1, P.2, B.1.1.374 and B.1.1.371. The method meets point-of-care requirements and can be deployed in the field for high-throughput COVID-19 testing campaigns, especially in countries where COVID-19 testing efforts are far from ideal to tackle the pandemics. Although RT-qPCR is considered the gold standard for SARS-CoV-2 RNA detection, it requires expensive equipments, infrastructure and highly trained personnel. In contrast, RT-LAMP emerges as an affordable, inexpensive and simple alternative for SARS-CoV-2 molecular detection that can be applied to massive COVID-19 testing campaigns and save lives.Competing Interest StatementH.R.M is part of Visuri company. Results presented here are the basis of a COVID-19 RT-LAMP diagnostic test offered by Visuri named OmniLAMP SARS-CoV-2 kit. P.A.A. and R.L.M.N. are scientific advisors at CEPHA Biotech. The other authors declare no financial or non-financial conflict of interestsFunding StatementThis work was funded by: Fundacao de Amparo a Pesquisa do Estado de Minas Gerais/Fapemig, grant number #APQ-00485-20, to RLMN; grant number #APQ-00262-20 to FDC and Fundacao Oswaldo Cruz/Inova Fiocruz Program/Innovative Products (grant number VPPIS-004-FIO-18-51) to RLMN; Innovative Products to face COVID-19 pandemics (grant number VPPIS/005-FIO-20-2-45) to PAA and from the MCTI/ Brazilian Ministry of Science, Technology and Innovation, through the Rede Virus initiative to PAA (grant number/FINEP 01.20.0005.00). EGO received a Masters fellowship from the Vice presidency of Education, Formation and communication VPEIC/Fundacao Oswaldo Cruz. IAB and APMFL received postdoctoral research fellowships from Inova Fiocruz Program/Fundacao Oswaldo Cruz. ABG holds a science, technology and innovation development scholarship from Fapemig (BDCTI/I). LAT is a postdoctoral fellow from MCTI (CNPq/DTI/A). RLMN, SMRT, GW and GLW are CNPq Research Fellows (#310640/2017-2; #302961/2017-8; #303902/2019-1; #307538/2019-2). PM holds a scholarship from Coordenacao de Aperfeicoamento de Nivel Superior (CAPES/Acao Emergencial).The funders had no role in the study design, data collection and analysis, decision to publish or manuscript preparation. PAA, GLW and RLMN are part of Fiocruz COVID-19 Genomic Surveillance NetworkAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All procedures involving human participants, collection and use of clinical samples and data were in accordance with ethical standards and approved by the Research Ethics Committee Involving Human Beings(local CEP) from Instituto Rene Rachou - Fundacao Oswaldo Cruz, which is part of the Brazilian regulatory system CEP/National Research Ethics Comission (CONEP). Ethical approval of the project entitled "Search for new diagnostic alternatives for COVID-19 and human respitratory diseases", coordinated by Dr. Pedro A. Alves; was issued on June 12, 2020 under license protocol number: 4084902; CAAE (certificate of presentation for ethical appreciation): 31984720300005091. Ethical approval was issued and signed by Dr. Ana Paula Granato Ribeiro, Head of the Research Ethics Committee INvolving Human Beings/Instituto Rene Rachou - Fundacao Oswaldo Cruz 1. National Research Ethics Comission, Brazil / Instituto Rene Rachou, Fundacao Oswaldo Cruz / Research Ethics Committee Involving Human Beings 2. Decision for ethical approval was made on June 12, 2020.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe genomes of SARS-CoV-2 VOI and VOCs generated are deposited on GSAID according to the following accession codes: EPI_ISL_500460, EPI_ISL_500461, EPI_ISL_500865, EPI_ISL_500868, EPI_ISL_500872, EPI_ISL_500477, EPI_ISL_500482, EPI_ISL_1239012, EPI_ISL_1239013, EPI_ISL_1239014, EPI_ISL_1239015, EPI_ISL_1239016; as previously published (Bezerra et al. 2021) Infect Genet Evol. 2021 May 8;92:104910. doi: 10.1016/j.meegid.2021.104910.